Telpres Plus 80mg/25mg, 28 tablets — Made in Spain — Free Delivery

Product description

Telpres Plus tablets are used for arterial hypertension. As a combination with a fixed dose, Telpres Plus is used when telmisartan monotherapy does not provide adequate blood pressure control.

Composition

The active substance is telmisartan and hydrochlorothiazide.

1 tablet contains telmisartan 40 mg and hydrochlorothiazide 12.5 mg telmisartan 80 mg and hydrochlorothiazide 12.5 mg, telmisartan 80 mg and hydrochlorothiazide 25 mg.

Excipients: mannitol (E 421), povidone, crospovidone, meglumine, sodium hydroxide, lactose, microcrystalline cellulose, hypromellose, sodium starch (type A), magnesium stearate, yellow iron oxide (E 172).

Contraindications

• hypersensitivity to any of the components of the preparation;
• hypersensitivity to other substances that are derivatives of sulfonamide (since hydrochlorothiazide is a sulfonamide derivative);
• pregnancy or planning a pregnancy;
• cholestatic and biliary obstructive disorders;
• severe liver dysfunction;
• anuria, severe renal dysfunction (creatinine clearance less than 30 ml / minute);
• refractory hypokalemia / hyponatremia, hypercalcemia;
• lactation;
• symptomatic hyperuricemia (gout);
• children's age (up to 18 years old);
• the simultaneous use of telmisartan and aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal failure (GFR <60 ml / minute / 1.73 m2).

Mode of application

Telpres is taken once a day with a sufficient amount of liquid, regardless of food intake.

Application features

Pregnancy

The preparation is contraindicated for use in pregnant women or women planning pregnancy. If pregnancy is confirmed during treatment with this preparation, its use must be stopped immediately and, if necessary, replaced with another preparation approved for use by pregnant women.

Children

Telmisartan is not recommended for use in children (under the age of 18) due to the lack of sufficient data on the safety and efficacy of the preparation.

Drivers

With antihypertensive therapy, including telmisartan, when driving vehicles or other mechanisms, it is necessary to take into account the possibility of dizziness or hypersomnia.

Overdose

Information on overdose of telmisartan in humans is limited. The level of withdrawal of hydrochlorothiazide by hemodialysis has not been established.

With an overdose of telmisartan, the most pronounced manifestations were arterial hypotension and tachycardia, bradycardia, dizziness, vomiting, increased serum creatinine levels and acute renal failure were also reported. An overdose of hydrochlorothiazide is associated with a decrease in the concentration of electrolytes (hypokalemia, hypochloremia) and hypovolemia due to excessive diuresis. The most common symptoms of an overdose are nausea and drowsiness. Hypokalemia can lead to muscle spasm and / or exacerbation of cardiac arrhythmias with concomitant use of digitalis glycosides or certain antiarrhythmic preparations.

Adverse Reactions

Serious adverse reactions, including anaphylactic reactions and angioedema, are rare (≥ 1/10 000 to <1/1000), and acute renal failure is also observed.

Interaction

The combination of telmisartan and aliskiren is contraindicated in patients with diabetes mellitus and impaired renal function (GFR <60 ml / min / 1.73 m2).

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C, out of the reach of children.

Shelf life is 3 years.